Evidence map›Paper›PMID 28222147›Full record

ArticlePloS one2017

The desert gerbil Psammomys obesus as a model for metformin-sensitive nutritional type 2 diabetes to protect hepatocellular metabolic damage: Impact of mitochondrial redox state.

Inès Gouaref, Dominique Detaille, Nicolas Wiernsperger, Naim Akhtar Khan, Xavier Leverve, Elhadj-Ahmed Koceir

Open access · goldFull text read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Role of glycolysis in diabetic atherosclerosis.World journal of diabetes · 2023
    Review
  3. Anti-Obesity and Anti-Dyslipidemic Effects ofFoods (Basel, Switzerland) · 2023
    Article
  4. Species Differences in Tryptophan Metabolism and Disposition.International journal of tryptophan research : IJTR · 2022
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 2 countries.

Inès GouarefBioenergetics and Intermediary Metabolism team, Laboratory of Biology and Organism Physiology, Biological Sciences Institute, University of Sciences and Technology Houari Boumediene, BP 32, ElAlia, Algiers, Algeria.
Dominique DetailleUniversité de Bordeaux, Rhythmology and Heart Modeling Institute, Bordeaux, France.
Nicolas WiernspergerCarMeN Laboratory, INSERM U1060, Villeurbanne, France.
Naim Akhtar KhanPhysiologie de la Nutrition & Toxicologie, INSERM U1236, Université de Bourgogne Franche-Comté (UBFC), Dijon, France.
Xavier LeverveUniversity Grenoble Alpes, Laboratoire de Bioénergétique Fondamentale et Appliquée (LBFA), INSERM, U1055, Grenoble, France.
Elhadj-Ahmed KoceirBioenergetics and Intermediary Metabolism team, Laboratory of Biology and Organism Physiology, Biological Sciences Institute, University of Sciences and Technology Houari Boumediene, BP 32, ElAlia, Algiers, Algeria.
Electrophysiology and Heart Modeling Institute · FRInserm · FRLaboratory of Fundamental and Applied Bioenergetics · FRUniversité Claude Bernard Lyon 1 · FRUniversité de Bourgogne · FRUniversity of Sciences and Technology Houari Boumediene · DZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWhile metformin (MET) is the most widely prescribed antidiabetic drug worldwide, its beneficial effects in Psammomys obesus (P. obesus), a rodent model that mimics most of the metabolic features of human diabetes, have not been explored thoroughly. Here, we sought to investigate whether MET might improve insulin sensitivity, glucose homeostasis, lipid profile as well as cellular redox and energy balance in P. obesus maintained on a high energy diet (HED). MATERIALS AND

methodsP. obesus gerbils were randomly assigned to receive either a natural diet (ND) consisting of halophytic plants (control group) or a HED (diabetic group) for a period of 24 weeks. MET (50 mg/kg per os) was administered in both animal groups after 12 weeks of feeding, i.e., the time required for the manifestation of insulin resistance in P. obesus fed a HED. Parallel in vitro experiments were conducted on isolated hepatocytes that were shortly incubated (30 min) with MET and energetic substrates (lactate + pyruvate or alanine, in the presence of octanoate).

resultsIn vivo, MET lowered glycemia, glycosylated haemoglobin, circulating insulin and fatty acid levels in diabetic P. obesus. It also largely reversed HED-induced hepatic lipid alterations. In vitro, MET increased glycolysis but decreased both gluconeogenesis and ketogenesis in the presence of glucogenic precursors and medium-chain fatty acid. Importantly, these changes were associated with an increase in cytosolic and mitochondrial redox states along with a decline in respiration capacity.

conclusionsMET prevents the progression of insulin resistance in diabetes-prone P. obesus, possibly through a tight control of gluconeogenesis and fatty acid β-oxidation depending upon mitochondrial function. While the latter is increasingly becoming a therapeutic issue in diabetes, the gut microbiota is another promising target that would need to be considered as well.

Indexed as

AnimalsDiabetes Mellitus, Type 2Disease Models, AnimalGerbillinaeHypoglycemic AgentsInsulin ResistanceLiverMaleMetforminMitochondria, LiverOxidation-ReductionHypoglycemic AgentsMetformin

Identifiers

PMID28222147
PMCPMC5319739
OpenAlexW2591242066

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.